Table 1.
Demographics of study population
| BMI 18.5–24.9 | BMI 25–29.9 | BMI > 30 | p value | |
|---|---|---|---|---|
| n (%) | 57 (24) | 62 (26) | 117 (50) | |
| Female n (%) | 36 (63) | 38 (62) | 84 (72) | 0.29 |
| Race n (%) | ||||
| White | 37 (65) | 35 (56) | 53 (45) | 0.02 |
| Black | 13 (23) | 18 (29) | 56 (48) | |
| Asian | 3 (5) | 3 (5) | 1 (1) | |
| Other | 4 (7) | 6 (10) | 6 (5) | |
| Ethnicity n (%) | ||||
| Hispanic | 4 (7) | 12 (20) | 21 (18) | 0.13 |
| Age | 36±15 | 42±141 | 42±121 | <0.01 |
| Age of asthma onset | 12.5±13.8 | 16.1±14.5 | 15.5±14.9 | 0.33 |
| Steroids in last 12 months | 21 (37%) | 20 (32%) | 49 (42%) | 0.44 |
| Atopya | 43 (75) | 56 (92) | 98 (82) | 0.06 |
| ACT (range 5–25↑) | 15.8±2.7 | 15.6±3.2 | 14.6±3.6 | 0.06 |
| ASUI (range 0–1↑) | 0.69±0.17 | 0.74±0.18 | 0.69±0.19 | 0.26 |
| MAQLQ (range 1–80↓) | 20.0±12.9 | 21.5±14.6 | 24.8±16.5 | 0.12 |
| FEV1 (% predicted) | 88.1±14.0 | 81.8±17.7 | 79.1±15.8b | < 0.01 |
| FVC (% predicted) | 98.5±14.5 | 93.8±16.1 | 88.2±15.2b | < 0.001 |
| FEV1/FVC (% predicted) | 88.8±10.5 | 86.5±10.5 | 88.7±9.8 | 0.34 |
| Exhaled Nitric Oxide (ppb) | 39.19±32.07 | 41.28±33.79 | 27.04±19.94b,c | <0.01 |
| Sinus Symptom Score (range 1–60↓) | 24.8±12.0 | 26.6±13.8 | 27.4±12.3 | 0.42 |
| SNOT 22 (range 0–120↓) | 35.4±18.5 | 40.2±22.8 | 39.1±21.7 | 0.43 |
| Nasal ECP (ng/ml) | 29.7±32.0 | 25.5±37.4 | 23.3±29.6 | 0.5 |
| Nasal CCL17 (ng/ml) | 22.0±13.4 | 25.4±18.8 | 24.7±21.0 | 0.88 |
| Serum ECP (ng/ml) | 19.3±19.6 | 12.7±12.2 | 17.7±31.2 | 0.32 |
| serum CCL17 (ng/ml) | 365±196 | 341±165 | 361±193 | 0.76 |
↑ higher score indicative of better control, ↓ lower score indicative of better control
a
Atopy defined as any skin test positive, 233 had skin tests
b
post hoc testing, p < 0.01 compared with lean group, and
c
p< 0.05 compared with overweight group (ANOVA followed by Bonferroni correction)